DUPLE, NCT06418087: Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC) |
|
|
| Recruiting | 2 | 49 | Europe | Durvalumab 50 MG/1 ML Intravenous Solution [IMFINZI], Carboplatino AHCL 10 mg/ml Concentrate for solution for infusion, Etoposide 20 mg/ml Concentrate for solution for infusion | Gruppo Oncologico Italiano di Ricerca Clinica | Pulmonary Large-cell Neuroendocrine Carcinoma | 12/26 | 12/26 | | |